ContraFect Corporation (Nasdaq:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced the pricing of its underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $2.00 per share.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,